LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Renal Expression of Immunomodulators in Diabetic Nephropathy

By LabMedica International staff writers
Posted on 12 Aug 2020
In situ expression of chemokines eotaxin, IL-8, and MIP-1α in glomerular and tubulointerstitial compartments in patients with diabetic nephropathy (DN) and control group (Photo courtesy of Federal University of Triângulo Mineiro).
In situ expression of chemokines eotaxin, IL-8, and MIP-1α in glomerular and tubulointerstitial compartments in patients with diabetic nephropathy (DN) and control group (Photo courtesy of Federal University of Triângulo Mineiro).
Diabetic nephropathy (DN) is a chronic microvascular complication that affects about 20% to 30% of patients with type 2 diabetes mellitus (T2DM). It is considered the leading cause of end-stage renal failure requiring renal replacement therapy.

Immune and inflammatory mechanisms play important role in the development and progression of DN, which is considered a chronic inflammatory disease. Several cells, such as monocytes, macrophages, and lymphocytes, as well as the immunomodulators chemokines and cytokines, have been implicated in this process.

Medical scientists at the Federal University of Triângulo Mineiro (Uberaba, Brazil) selected 44 native renal biopsies from patients with DN and 23 control cases. The diagnosis of DN was performed with three samples used for light microscopy (LM), direct immunofluorescence (IF) and transmission electron microscopy (TEM). For LM, 2-μm paraffin sections were stained with hematoxylin and eosin (H&E), Sirius red, methenamine silver, and Masson’s trichrome. LM was used to analyze morphological changes and interstitial inflammation.

Immunohistochemistry was performed manually on slides containing paraffin-embedded tissue sections using the Novolink Polymer Detection System Kit, a non-biotin polymer system (Leica Biosystems, Nussloch, Germany; www.leicabiosystems.com). In situ expression of eotaxin, macrophage inflammatory protein-1α (MIP-1α), interleukin-8 (IL-8), IL-4, IL-10, tumor necrosis factor-α (TNF-α ), tumor necrosis factor receptor-1 (TNFR1), IL-1β, and IL-6 were evaluated by immunohistochemistry. Immunostained cells showing an intense brownish staining were marked by the observer using the interactive AxionCam ICc 5 image analysis system (Carl Zeiss Microscopy GmbH, Jena, Germany; www.zeiss.de).

The team reported that the DN group showed a significant increase in IL-6, IL-1β, IL-4 and eotaxin expression, and a decrease in TNFR1 and IL-8 expression compared to the control group. However, there were no significant differences in IL-10, TNF-α, and MIP-1α expression among groups. With interstitial inflammation, there was a significant increase in IL-6 in scores 0 and 1 compared to score 2 , in IL-10 in score 2 compared to score 0, and in eotaxin in score 2 compared to scores 0 and 1, whereas IL-8 and MIP-1α showed no significant differences. There was a tendency for negative correlation between eotaxin and estimated glomerular filtration rate (eGFR).

The authors concluded that that in situ expression of cytokines and chemokines, including IL-6, IL-1β, IL-4 and eotaxin, is increased in patients with DN. It was observed that, possibly, eotaxin may have an important role in progression of interstitial inflammation in DN and in the decrease of eGFR of these patients. The study was published on July 28, 2020 in the journal BMC Nephrology.


Related Links:

Federal University of Triângulo Mineiro
Leica Biosystems
Carl Zeiss Microscopy
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more